Gilead Sciences (GILD) 97.65 $GILD
Most active Nasdaq-traded stocks
AP - 40 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 17.31 (-0.13), MU: 32.87 (-0.91), FITB: 18.81 (-0.79), GILD: 97.65 (+0.86), FB: 76.15 (-1.04), AMAT: 23.25 (-0.91), CMCSK: 54.87 (-0.71), MSFT: 45.65 (-0.68), INTC: 35.28 (-0.67), AAPL: 106.26 (+0.01), CMCSA: 55.23 (-0.73), CSCO: 27.05 (-0.01)
Final Glance: Biotechnology companies
AP - 40 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
2015 Biotech Stock Preview: Rhythms Of The 'PermaBull'
Rod Raynovich - Seeking Alpha - Tue Jan 06, 2:33PM CST
2015: Another Good Year Unless "Something Happens" Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as...
ESRX: 83.28 (-0.94), GILD: 97.65 (+0.86), FBT: 101.17 (-1.66), ABBV: 64.33 (-0.32), XLV: 68.05 (-0.23)
Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions
at The Street - Tue Jan 06, 2:08PM CST
In a blow to investor transparency, an embarrassingly small number of healthcare companies are webcasting their Q&A breakout sessions at next week's J.P. Morgan Healthcare Conference.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), VRTX: 117.36 (-3.67), ISIS: 65.44 (-2.73), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), AGIO: 111.43 (+2.56), BMY: 58.48 (-0.10), CELG: 110.51 (-1.42)
Assessing Gilead's Reality-Perception Gap: Upside Revenue Surprise
lmvus - at Seeking Alpha - Tue Jan 06, 1:32PM CST
GILD: 97.65 (+0.86), ARWR: 6.95 (-0.55)
Midday Glance: Biotechnology companies
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
at The Street - Tue Jan 06, 10:52AM CST
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), QCOR: 93.60 (+1.52), ISIS: 65.44 (-2.73), GILD: 97.65 (+0.86), PFE: 31.42 (+0.26), VVUS: 2.94 (-0.10), JUNO: 51.66 (+5.71), BMY: 58.48 (-0.10), MNKD: 5.57 (-0.13), ARNA: 3.32 (-0.20), PBYI: 188.12 (-0.25), CELG: 110.51 (-1.42)
Walgreen Year-End Sales Jump On Flu Prescriptions
at Investor's Business Daily - Tue Jan 06, 10:39AM CST
Walgreen Boots Alliance (WBA) reported a robust rise in sales in December on strong prescriptions in a heavy flu season. Overall sales climbed 10.2% in December vs. the same month the year before, pushing shares up 1.2% shortly after the market...
WBA: 74.69 (+0.19), GILD: 97.65 (+0.86), CVS: 94.23 (+0.07), RAD: 7.71 (+0.19)
Jim Cramer: Why Are You Shorting Innovative Biotech Stocks?
at The Street - Tue Jan 06, 10:37AM CST
Cramer says investors shouldn't short-sell biotechs because they are innovators. Look at Alkermes' latest success with treating depression.
GILD: 97.65 (+0.86), AGIO: 111.43 (+2.56), CVX: 108.03 (-0.05), ALKS: 60.93 (+1.55), REGN: 396.89 (-15.58)
Global Cystic Fibrosis Market 2015-2019: Dominant Vendors Include Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis & Vertex Pharmaceuticals
M2 - Tue Jan 06, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mlcm5/global_cystic) has announced the addition of the "Global Cystic Fibrosis Market 2015-2019" report to their offering. The analysts forecast the Global Cystic Fibrosis market to grow at a CAGR of 32.5% over the period 2014-2019 Cystic fibrosis also known as mucoviscidosis is a genetically-inherited disease. It is one of the most common genetic disorders found in the Caucasian children. The incidence of cystic fibrosis varies among populations, and is substantially less common in Asian and African populations as compared to the people of Caucasoid origin of Europe and North America, with a marked difference within each country. CFTR modulator drugs are increasingly becoming the preferred choice of treatment for cystic fibrosis as these drugs target the molecular cause of cystic fibrosis. Since these drugs target the cause of the disease, they are gaining popularity among patients and the medical community as a preferred choice for the treatment of cystic fibrosis. According to the report, the primary driver of this market is the high degree of unmet needs for appropriate drugs in the market. There is no cure for cystic fibrosis and the mortality rate is high. Therefore, drugs that can achieve remission of the disease in patients are expected to drive the growth of the market. Further, the report states that the high cost of therapy is a major factor that restricts the growth of the market. Patients tend to withdraw from treatment, deterred by the high costs. Medication and hospitalization costs account for the largest share of the expenditure of a cystic fibrosis patient, followed by medical services, costs resulting from other complications, and diagnostic charges. This results in high overall expenditure. The report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis which includes: - Small Molecules - Biologics Key Vendors - Actavis - F. Hoffmann-La Roche - Gilead Sciences - Novartis - Vertex Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Market Segmentation by Molecule Type - Market Segmentation by Route of Administration - Market Segmentation by Dosage Form - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/9m...bal_cystic
VRTX: 117.36 (-3.67), GILD: 97.65 (+0.86), NVS: 91.67 (-0.78)
Gilead Acquires Drug Program For Fatty Liver Disease
at Investor's Business Daily - Tue Jan 06, 10:20AM CST
Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470...
RPTP: 10.28 (-0.33), GILD: 97.65 (+0.86), CNAT: 10.63 (+0.57), ICPT: 160.01 (-16.99), FGEN: 35.06 (+1.27)
Cramer: Gilead 'Back in the Driver's Seat' After CVS Deal
at The Street - Tue Jan 06, 10:04AM CST
TheStreet's Jim Cramer says Gilead Sciences is attractive given its large cash position, low valuation and recent deal with CVS Health.
BIIB: 334.65 (-2.09), ESRX: 83.28 (-0.94), GILD: 97.65 (+0.86), CVS: 94.23 (+0.07), ABBV: 64.33 (-0.32), REGN: 396.89 (-15.58), CELG: 110.51 (-1.42)
Gilead Sciences to buy liver disease treatment from Phenex
AP - Tue Jan 06, 9:58AM CST
NEW YORK (AP) — Gilead Sciences Inc. is increasing its focus on treating liver diseases by paying as much as $470 million to buy a treatment being developed by privately held Phenex Pharmaceuticals AG.
GILD: 97.65 (+0.86)
Early Glance: Biotechnology companies
AP - Tue Jan 06, 9:37AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 7.99 (-0.68), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), OPK: 9.91 (-0.15), MRK: 60.32 (+2.28), IBB: 300.81 (-5.04), AGIO: 111.43 (+2.56), TEVA: 54.93 (-0.16), CELG: 110.51 (-1.42)
Brian Nelson: 4 Top Ideas To Consider In 2015
Brian Nelson - at Seeking Alpha - Tue Jan 06, 8:29AM CST
COH: 36.30 (-0.43), EMN: 73.53 (-0.31), GILD: 97.65 (+0.86), MSFT: 45.65 (-0.68)
Gilead buys liver disease drug development platform
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 8:23AM CST
GILD: 97.65 (+0.86)
Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals' Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Business Wire - Tue Jan 06, 7:30AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) and Phenex Pharmaceuticals AG, a privately-held biotechnology company, today announced the signing of a definitive agreement under which Gilead will acquire Phenex's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Under the terms of the agreement, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.
GILD: 97.65 (+0.86)
2015 Stock Picks: 19 Out Of 300
Dark-Liquidity - at Seeking Alpha - Tue Jan 06, 6:59AM CST
GD: 135.72 (+0.16), SPTN: 25.15 (-0.49), VMW: 78.79 (-2.24), CACC: 134.78 (-0.43), DAL: 47.22 (-1.14), LKQ: 26.95 (-0.48), PCP: 230.98 (-2.38), GIB: 36.90 (-0.57), LUV: 40.46 (-1.18), SWK: 93.03 (-0.94), SPY: 199.82 (-1.90), QQQ: 100.07 (-1.36), MRVL: 14.82 (+0.54), GILD: 97.65 (+0.86), ANIP: 52.21 (-3.77), CNI: 65.11 (-0.85), RHT: 67.50 (-0.59), FFIV: 126.73 (-3.03), BSFT: 28.43 (-0.67), FL: 54.44 (-1.45), CTSH: 50.98 (-1.36), CBS: 53.19 (-1.07)
Most active Nasdaq-traded stocks
AP - 40 mins ago
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SPLS: 17.31 (-0.13), MU: 32.87 (-0.91), FITB: 18.81 (-0.79), GILD: 97.65 (+0.86), FB: 76.15 (-1.04), AMAT: 23.25 (-0.91), CMCSK: 54.87 (-0.71), MSFT: 45.65 (-0.68), INTC: 35.28 (-0.67), AAPL: 106.26 (+0.01), CMCSA: 55.23 (-0.73), CSCO: 27.05 (-0.01)
Final Glance: Biotechnology companies
AP - 40 mins ago
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
2015 Biotech Stock Preview: Rhythms Of The 'PermaBull'
Rod Raynovich - Seeking Alpha - Tue Jan 06, 2:33PM CST
2015: Another Good Year Unless "Something Happens" Life Science stocks had another big year in 2014 up 48% tracking gains for the overall healthcare sector up 35%. Over 10 years the return is 300%! The move up was not a straight line as...
ESRX: 83.28 (-0.94), GILD: 97.65 (+0.86), FBT: 101.17 (-1.66), ABBV: 64.33 (-0.32), XLV: 68.05 (-0.23)
Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions
at The Street - Tue Jan 06, 2:08PM CST
In a blow to investor transparency, an embarrassingly small number of healthcare companies are webcasting their Q&A breakout sessions at next week's J.P. Morgan Healthcare Conference.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), VRTX: 117.36 (-3.67), ISIS: 65.44 (-2.73), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), AGIO: 111.43 (+2.56), BMY: 58.48 (-0.10), CELG: 110.51 (-1.42)
Assessing Gilead's Reality-Perception Gap: Upside Revenue Surprise
lmvus - at Seeking Alpha - Tue Jan 06, 1:32PM CST
GILD: 97.65 (+0.86), ARWR: 6.95 (-0.55)
Midday Glance: Biotechnology companies
AP - Tue Jan 06, 12:17PM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Fifteen Fabulously Intelligent Biotech Stock Predictions for 2015
at The Street - Tue Jan 06, 10:52AM CST
TheStreet's Adam Feuerstein lays down his predictions for the biotech industry for 2015.
BLUE: 95.24 (+3.19), BIIB: 334.65 (-2.09), QCOR: 93.60 (+1.52), ISIS: 65.44 (-2.73), GILD: 97.65 (+0.86), PFE: 31.42 (+0.26), VVUS: 2.94 (-0.10), JUNO: 51.66 (+5.71), BMY: 58.48 (-0.10), MNKD: 5.57 (-0.13), ARNA: 3.32 (-0.20), PBYI: 188.12 (-0.25), CELG: 110.51 (-1.42)
Walgreen Year-End Sales Jump On Flu Prescriptions
at Investor's Business Daily - Tue Jan 06, 10:39AM CST
Walgreen Boots Alliance (WBA) reported a robust rise in sales in December on strong prescriptions in a heavy flu season. Overall sales climbed 10.2% in December vs. the same month the year before, pushing shares up 1.2% shortly after the market...
WBA: 74.69 (+0.19), GILD: 97.65 (+0.86), CVS: 94.23 (+0.07), RAD: 7.71 (+0.19)
Jim Cramer: Why Are You Shorting Innovative Biotech Stocks?
at The Street - Tue Jan 06, 10:37AM CST
Cramer says investors shouldn't short-sell biotechs because they are innovators. Look at Alkermes' latest success with treating depression.
GILD: 97.65 (+0.86), AGIO: 111.43 (+2.56), CVX: 108.03 (-0.05), ALKS: 60.93 (+1.55), REGN: 396.89 (-15.58)
Global Cystic Fibrosis Market 2015-2019: Dominant Vendors Include Actavis, F. Hoffmann-La Roche, Gilead Sciences, Novartis & Vertex Pharmaceuticals
M2 - Tue Jan 06, 10:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/9mlcm5/global_cystic) has announced the addition of the "Global Cystic Fibrosis Market 2015-2019" report to their offering. The analysts forecast the Global Cystic Fibrosis market to grow at a CAGR of 32.5% over the period 2014-2019 Cystic fibrosis also known as mucoviscidosis is a genetically-inherited disease. It is one of the most common genetic disorders found in the Caucasian children. The incidence of cystic fibrosis varies among populations, and is substantially less common in Asian and African populations as compared to the people of Caucasoid origin of Europe and North America, with a marked difference within each country. CFTR modulator drugs are increasingly becoming the preferred choice of treatment for cystic fibrosis as these drugs target the molecular cause of cystic fibrosis. Since these drugs target the cause of the disease, they are gaining popularity among patients and the medical community as a preferred choice for the treatment of cystic fibrosis. According to the report, the primary driver of this market is the high degree of unmet needs for appropriate drugs in the market. There is no cure for cystic fibrosis and the mortality rate is high. Therefore, drugs that can achieve remission of the disease in patients are expected to drive the growth of the market. Further, the report states that the high cost of therapy is a major factor that restricts the growth of the market. Patients tend to withdraw from treatment, deterred by the high costs. Medication and hospitalization costs account for the largest share of the expenditure of a cystic fibrosis patient, followed by medical services, costs resulting from other complications, and diagnostic charges. This results in high overall expenditure. The report considers the revenue generated from the sales of various generic and branded therapies used in the treatment of cystic fibrosis which includes: - Small Molecules - Biologics Key Vendors - Actavis - F. Hoffmann-La Roche - Gilead Sciences - Novartis - Vertex Pharmaceuticals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Disease Overview - Market Landscape - Market Segmentation by Molecule Type - Market Segmentation by Route of Administration - Market Segmentation by Dosage Form - Geographical Segmentation - Key Leading Countries - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/9m...bal_cystic
VRTX: 117.36 (-3.67), GILD: 97.65 (+0.86), NVS: 91.67 (-0.78)
Gilead Acquires Drug Program For Fatty Liver Disease
at Investor's Business Daily - Tue Jan 06, 10:20AM CST
Big-cap biotech Gilead Sciences (GILD) agreed Tuesday to acquire a program from small German biotech Phenex Pharmaceuticals aimed at treating liver disease. Gilead agreed to an unspecified upfront payment and milestone payments totaling up to $470...
RPTP: 10.28 (-0.33), GILD: 97.65 (+0.86), CNAT: 10.63 (+0.57), ICPT: 160.01 (-16.99), FGEN: 35.06 (+1.27)
Cramer: Gilead 'Back in the Driver's Seat' After CVS Deal
at The Street - Tue Jan 06, 10:04AM CST
TheStreet's Jim Cramer says Gilead Sciences is attractive given its large cash position, low valuation and recent deal with CVS Health.
BIIB: 334.65 (-2.09), ESRX: 83.28 (-0.94), GILD: 97.65 (+0.86), CVS: 94.23 (+0.07), ABBV: 64.33 (-0.32), REGN: 396.89 (-15.58), CELG: 110.51 (-1.42)
Gilead Sciences to buy liver disease treatment from Phenex
AP - Tue Jan 06, 9:58AM CST
NEW YORK (AP) — Gilead Sciences Inc. is increasing its focus on treating liver diseases by paying as much as $470 million to buy a treatment being developed by privately held Phenex Pharmaceuticals AG.
GILD: 97.65 (+0.86)
Early Glance: Biotechnology companies
AP - Tue Jan 06, 9:37AM CST
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
GILD: 97.65 (+0.86), AMGN: 152.90 (-5.09), CELG: 110.51 (-1.42)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 7.99 (-0.68), SGEN: 31.45 (-1.60), GILD: 97.65 (+0.86), OPK: 9.91 (-0.15), MRK: 60.32 (+2.28), IBB: 300.81 (-5.04), AGIO: 111.43 (+2.56), TEVA: 54.93 (-0.16), CELG: 110.51 (-1.42)
Brian Nelson: 4 Top Ideas To Consider In 2015
Brian Nelson - at Seeking Alpha - Tue Jan 06, 8:29AM CST
COH: 36.30 (-0.43), EMN: 73.53 (-0.31), GILD: 97.65 (+0.86), MSFT: 45.65 (-0.68)
Gilead buys liver disease drug development platform
Seeking Alpha - at Seeking Alpha - Tue Jan 06, 8:23AM CST
GILD: 97.65 (+0.86)
Gilead Sciences Announces Acquisition of Phenex Pharmaceuticals' Development Program for Non-Alcoholic Steatohepatitis (NASH) and Other Liver Diseases
Business Wire - Tue Jan 06, 7:30AM CST
Gilead Sciences, Inc. (Nasdaq:GILD) and Phenex Pharmaceuticals AG, a privately-held biotechnology company, today announced the signing of a definitive agreement under which Gilead will acquire Phenex's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for the treatment of liver diseases including nonalcoholic steatohepatitis (NASH). Under the terms of the agreement, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.
GILD: 97.65 (+0.86)
2015 Stock Picks: 19 Out Of 300
Dark-Liquidity - at Seeking Alpha - Tue Jan 06, 6:59AM CST
GD: 135.72 (+0.16), SPTN: 25.15 (-0.49), VMW: 78.79 (-2.24), CACC: 134.78 (-0.43), DAL: 47.22 (-1.14), LKQ: 26.95 (-0.48), PCP: 230.98 (-2.38), GIB: 36.90 (-0.57), LUV: 40.46 (-1.18), SWK: 93.03 (-0.94), SPY: 199.82 (-1.90), QQQ: 100.07 (-1.36), MRVL: 14.82 (+0.54), GILD: 97.65 (+0.86), ANIP: 52.21 (-3.77), CNI: 65.11 (-0.85), RHT: 67.50 (-0.59), FFIV: 126.73 (-3.03), BSFT: 28.43 (-0.67), FL: 54.44 (-1.45), CTSH: 50.98 (-1.36), CBS: 53.19 (-1.07)
